Salt Lake City-based AI-driven drug discovery company Recursion announced a 20% workforce reduction, reflecting pipeline pruning and a challenging capital environment. The restructuring aims to extend cash runway through 2027 while navigating the maturation phase of its Recursion 2.0 platform, integrating data, automation, and AI models for drug discovery. The layoffs represent a contraction from previous growth and highlight broader investor caution in biotech funding during 2025.